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Abstract
Background: The human immunodeficiency virus Vif protein overcomes the inhibitory activity of
the APOBEC3G cytidine deaminase by prohibiting its packaging into virions. Inhibition of
APOBEC3G encapsidation is paralleled by a reduction of its intracellular level presumably caused
by the Vif-induced proteasome-dependent degradation of APOBEC3G.
Results: In this report we employed confocal microscopy to study the effects of Vif on the
expression of APOBEC3G on a single cell level. HeLa cells dually transfected with Vif and
APOBEC3G expression vectors revealed efficient co-expression of the two proteins. Under
optimal staining conditions approximately 80% of the transfected cells scored double-positive for
Vif and APOBEC3G. However, the proportion of double-positive  cells observed in identical
cultures varied dependent on the fixation protocol and on the choice of antibodies used ranging
from as low as 40% to as high as 80% of transfected cells. Importantly, single-positive cells
expressing either Vif or APOBEC3G were observed both with wild type Vif and a biologically
inactive Vif variant. Thus, the lack of APOBEC3G in some Vif-expressing cells cannot be attributed
to Vif-induced degradation of APOBEC3G. These findings are consistent with our results from
immunoblot analyses that revealed only moderate effects of Vif on the APOBEC3G steady state
levels. Of note, viruses produced under such conditions were fully infectious demonstrating that
the Vif protein used in our analyses was both functional and expressed at saturating levels.
Conclusions: Our results suggest that Vif and APOBEC3G can be efficiently co-expressed. Thus,
depletion of APOBEC3G from Vif expressing cells as suggested previously is not a universal
property of Vif and thus is not imperative for the production of infectious virions.
Background
Replication of human immunodeficiency virus type 1
(HIV-1) in most primary cells and some immortalized T
cell lines is dependent on the expression of a functional
Vif protein. In the absence of Vif, virus replication is
restricted by a host factor that was recently identified as
CEM15 (now referred to as APOBEC3G) [1], a host cyti-
dine deaminase targeting DNA substrates in vitro [2] but
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whose role in normal cells is unknown. In the absence of
Vif, APOBEC3G is efficiently incorporated into virus par-
ticles [3-9] where it causes extensive cytidine to uracil
changes on the viral minus-strand cDNA during reverse
transcription [5,10-12]. The conversion of cytidine to
deoxyuridine on the minus-strand cDNA either results in
guanine to adenine changes on the viral plus-strand cDNA
to yield highly mutated viral genomes or triggers the deg-
radation of the deaminated minus strand cDNA through
the action of a DNA repair mechanism that involves
removal of the uracil base by uracil DNA glycosylase and
subsequent endonucleolytic cleavage at the abasic sites by
apyrimidinic endonuclease (reviewed in [13,14]). While
both mechanisms are detrimental to virus replication, the
reported inability of vif-defective viruses grown in restric-
tive cells to reverse transcribe the viral genome into full-
length cDNA is more consistent with the latter mecha-
nism involving the degradation of deaminated viral cDNA
[15-19].
Vif is a 23-kDa basic protein that is expressed late during
infection in a Rev-dependent manner [20]. Immunocyto-
chemical analyses revealed a largely cytoplasmic localiza-
tion of Vif [21-23]. However, Vif is efficiently
incorporated into HIV particles during productive infec-
tion through an interaction with viral genomic RNA and
associates with viral nucleoprotein complexes [22,24-26].
In the presence of Vif, the steady-state levels of cell-associ-
ated APOBEC3G – as judged by immunoblot analysis –
are reduced by 3–10 fold [3-8,27,28]. This Vif-dependent
reduction in APOBEC3G levels has been attributed to pro-
teasome-dependent degradation of the protein and
requires a direct interaction of Vif with APOBEC3G [3,6-
8].
Like Vif, APOBEC3G is a cytoplasmic protein. In fact, co-
immunoprecipitation analyses demonstrated an interac-
tion of Vif and APOBEC3G in transiently transfected cells
[3,5,6,27,29-32]. The formation of stable Vif:APOBEC3G
complexes seemed to be at odds with the reported protea-
some-dependent degradation of APOBEC3G in Vif-
expressing cells [3,6-9,27,28]. Indeed, the identification
of Vif:APOBEC3G complexes in mixtures of cell extracts
that had been individually transfected to express either Vif
or APOBEC3G suggested that the stable interaction of Vif
and APOBEC3G during co-immunoprecipitation may
occur after cell lysis [6]. Thus, the co-immunoprecipita-
tion of Vif and APOBEC3G from cell extracts is not neces-
sarily an indication of the existence of stable intracellular
complexes. Quite to the contrary, Marin et al reported a
profound effect of Vif on the expression of APOBEC3G on
a single cell level. They found that expression of Vif in
transiently transfected COS7 cultures resulted in an
almost complete segregation of cells expressing either
APOBEC3G or Vif [6]. Interestingly, this segregation of Vif
and APOBEC3G into separate cells was seen only for wild
type Vif. In fact, only 10% of cells expressing wild type Vif
were double-positive while 95% of cells expressing an
inactive Vif variant also contained APOBEC3G [6].
The current study aims at characterizing in more detail the
effects of Vif on the expression of human APOBEC3G on
a single cell level. The study was initiated because of the
apparent discrepancy between the drastic effects of Vif on
APOBEC3G reported by Marin et al and our own finding
of only moderate effects of Vif on APOBEC3G expression
in transiently transfected cells. In our study, Vif was
expressed from a subviral construct in a Tat- and Rev-
dependent manner while APOBEC3G was expressed
either in a Tat-dependent manner from an HIV-1-LTR-
based vector or independently from a CMV-promoter-
based expression vector. The Tat-dependent APOBEC3G
expression vector was used to restrict APOBEC3G expres-
sion to cells also expressing Tat (and thus Vif).
Confocal microscopic analysis of HeLa cells transiently
transfected with Vif and APOBEC3G expression vectors
revealed significant variations in the number of double-
positive cells in identical samples ranging from as low as
40% to as high as 80% of transfected cells depending on
fixation method and antibodies employed. Importantly,
the appearance of cells expressing only Vif or APOBEC3G
was observed both with wild type Vif and a biologically
inactive variant and thus cannot be explained by Vif-
induced degradation of APOBEC3G. Finally, despite the
efficient co-expression of Vif and APOBEC3G, viruses pro-
duced in these cultures were fully infectious. We therefore
conclude that the Vif-induced exclusion of APOBEC3G
from virus-producing cells reported by Marin et al [6] does
not apply to our system and because of that is not a uni-
versal property of all Vif proteins. This implies that elimi-
nation of APOBEC3G is not an obligate requirement for
the production of infectious viruses from APOBEC3G-
expressing cells.
Results
Expression of Vif in the context of a proviral vector only 
moderately reduces cellular APOBEC3G levels
A number of previous studies reported the efficient Vif-
dependent degradation of APOBEC3G by cellular protea-
somes [3,6,8,28]. However, we and others noted only a
moderate reduction of the cellular APOBEC3G levels in
response to Vif expression [4,5]. This is exemplified in fig-
ure 1 where APOBEC3G was expressed either in the pres-
ence or absence of Vif. Specifically, HeLa cells were
transfected with pcDNA-APO3G together either with wild
type pNL-A1 (Fig. 1A, lane 2) or its vif-defective variant,
pNL-A1vif(-) (lane 3). Mock transfected cells were
included as a control (lane 1). Cells were harvested 24 hr
post-transfection and whole-cell lysates were subjected toRetrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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immunoblot analysis as described in Methods using an
APOBEC3G-specific polyclonal antibody (Fig. 1A, top
panel) or a Vif-specific monoclonal antibody (Fig. 1A,
middle panel). To control for loading errors, the filters
were re-probed with an antibody to α-tubulin (Fig. 1A,
bottom panel). Consistent with our previous results,
expression of Vif from pNL-A1 only moderately reduced
the steady-state levels of APOBEC3G in HeLa cells. Quan-
titation of the data confirmed that expression of
APOBEC3G in the presence of Vif was reduced by only
about 20% (Fig. 1B).
Co-expression of APOBEC3G and Vif in HeLa cells
An earlier study investigating the coexpression of Vif and
APOBEC3G by confocal microscopy concluded that
APOBEC3G was virtually excluded from Vif-expressing
COS7 cells [6]. To verify this observation, we investigated
the effects of Vif on APOBEC3G expression on a single cell
level by performing a series of immunocytochemical anal-
yses. For that purpose, HeLa cells were transfected with
the Vif expression vector pNL-A1 together with pcDNA-
APO3G for the expression of human APOBEC3G. Cells
were grown on cover slips, fixed 24 hr later with cold
methanol, and stained with antibodies to APOBEC3G
(Fig. 2, panels A & D) and Vif (panels B & E). The results
of this experiment show that APOBEC3G can be expressed
in Vif-positive cells (white arrow heads) without a dra-
matic reduction in its expression level when compared to
Vif-negative cells (yellow arrow heads). Furthermore,
these data confirm that APOBEC3G is localized to the
cytoplasm while Vif was observed in this experiment in
some cells both in the cytoplasm and the nuclei of cells
(red arrow heads). Finally, we also observed cells express-
ing Vif that were APOBEC3G-negative (blue arrow heads).
Overlay of the Vif and APOBEC3G channels revealed a
partial co-localization of Vif and APOBEC3G in the cyto-
plasm apparent by the yellow staining in panels C & F of
figure 2. Interestingly, a significant number of cells in this
experiment were single-positive expressing either
APOBEC3G or Vif alone. The appearance of Vif-positive,
Vif has a moderate effect on APOBEC3G steady-state levels Figure 1
Vif has a moderate effect on APOBEC3G steady-state levels. (A) HeLa cells were transfected with pNL-A1 and pcDNA-
APO3G vector DNA at a 4:1 ratio. As control, mock-transfected cells (lane 1) and cells transfected with the Vif-deficient pNL-
A1∆Vif construct and pcDNA-APO3G vector DNA at a 4:1 ratio (lane 3) were included. Cell lysates were processed for 
immunoblotting as described in Methods and APOBEC3G and Vif-specific proteins were identified using an APOBEC3G-spe-
cific polyclonal antibody (α-APO3G) or a Vif-specific monoclonal antibody #319 (α-Vif). Tubulin was identified using an anti-
body to α-tubulin. (B) APOBEC3G-specific bands were acquired by densitometric scanning of the film and were quantified 
using the Fuji ImageGauge 4.0 software (Fuji Photofilm Co, LTD). Results are expressed as percent of the Vif-negative control, 
which was defined as 100%.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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APOBEC3G-negative cells could be explained by a Vif-
dependent restriction of APOBEC3G expression as pro-
posed by Marin et al [6]. However, cells expressing Vif
only were rare when compared to cells expressing
APOBEC3G alone (data not shown). The preponderance
of APOBEC3G single positive cells cannot be explained by
a Vif-dependent restriction but more likely represents a
technical, albeit reproducible, artifact.
Tat-dependent expression of APOBEC3G reduces the 
fraction of single-positive cells
In the experiment shown in figure 2, APOBEC3G was
expressed under the control of a CMV promoter while Vif
was expressed from the HIV-LTR promoter under the reg-
ulatory control of Tat and Rev. Because of the independ-
ent expression of Vif and APOBEC3G it cannot be ruled
out that the large number of single-positive cells in that
experiment – while statistically improbable – was caused
by the selective transfection of cells with either the Vif or
the APOBEC3G expression vector. To check this possibil-
ity, we expressed APOBEC3G from the HIV-1 long termi-
nal repeat (LTR) promoter driven vector pHIV-APO3G
[4]. Because of its dependence on Tat, APOBEC3G expres-
sion from pHIV-APO3G is restricted to cells also express-
ing Vif. Indeed, transfection of pHIV-APO3G into cells in
the absence of pNL-A1 or any other Tat expression vector
Co-expression of Vif and APOBEC3G in HeLa cells Figure 2
Co-expression of Vif and APOBEC3G in HeLa cells. HeLa cells were transfected with pNL-A1 and pcDNA-APO3G at a 1:1 
molar ratio. Transfected cells were grown on cover slips, fixed in methanol and processed for confocal microscopic analysis as 
described in Methods. Cells were stained with a rabbit polyclonal antibody to APOBEC3G (A & D) and a monoclonal Vif anti-
body (B & E). APOBEC3G was visualized using a Texas red-conjugated secondary antibody; Vif was visualized with a Cy2-con-
jugated secondary antibody. Panels C and F are merged images of panels A & B and D & E, respectively. Arrow heads are 
defined as follows: white = APOBEC3G:Vif-double-positive cells; yellow = Vif-negative cells; red = cells exhibiting nuclear and 
cytoplasmic staining for Vif.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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did not reveal any APOBEC3G expression as judged by
immunofluorescence analysis or immunoblotting
attesting to the strict Tat-dependence of this APOBEC3G
expression vector (data not shown).
In addition of measuring the context-dependent expres-
sion of APOBEC3G, we also wanted to determine the
influence of the fixation procedure on the efficiency of
Vif:APOBEC3G co-staining. It is well known that the
choice of fixative can affect the ability of a given antibody
to recognize a specific epitope on its target protein. Fre-
quently, epitopes are masked because of the folding prop-
erties of a protein in vivo or because of pre-existing
protein-protein interactions that may compete for anti-
body binding. To test this possibility we compared a for-
maldehyde fixation procedure employed previously [6]
with the methanol fixation procedure employed in our
own studies [22].
HeLa cells were transfected with pNL-A1 and pHIV-
APO3G at a 1:1 molar ratio. Cells were fixed 24 hr later
either with methanol (MeOH) as in figure 2 or with for-
maldehyde (FA) as described in Methods. Cells were
stained with Vif- and APOBEC3G-specific antibodies as
described in figure 2. The results of this experiment show
that expression of APOBEC3G under the control of the
HIV-1 LTR indeed increased the proportion of double-
positive cells both in methanol-fixed samples (Fig. 3, pan-
els A-C) and formaldehyde-fixed specimens (Fig. 3, panels
D-F). This suggests that the high proportion of single-pos-
itive cells observed in figure 2 was not the result of a Vif-
dependent restriction of APOBEC3G but was caused by
the independent expression of APOBEC3G from a Tat-
independent promoter. Again, in methanol-fixed samples
APOBEC3G expression levels in Vif-positive cells (Fig. 3A,
white arrow heads) were indistinguishable from those
observed for neighboring Vif-negative cells (Fig. 3A, yel-
low arrow head). Interestingly, the APOBEC3G fluores-
cent intensity appeared to be reduced in Vif-positive
formaldehyde-fixed specimens when compared to Vif-
negative cells or cells expressing low levels of Vif (Fig. 3D;
compare white and yellow arrow heads). Because the
methanol-fixed samples did not show a Vif-dependent
reduction in APOBEC3G signals in these experiments, we
conclude that the reduction in APOBEC3G signals
observed in formaldehyde-fixed samples is not the result
of Vif-induced degradation of APOBEC3G but is a techni-
cal artifact.
Co-expression of Vif and APOBEC3G: Protein degradation 
or epitope masking?
For a more quantitative analysis and to determine possi-
ble effects that arise from the use of different antibodies,
we extended the experiment shown in figure 3 to include
three different antibodies for the identification of
APOBEC3G. As before, HeLa cells were co-transfected
with a 1:1 ratio of pNL-A1 and pHIV-APO3G plasmid
DNAs. Cells were grown on cover slips and fixed 24 hr
later either with formaldehyde (Fig. 4, panels A-C) or
methanol (panels D-F) as described in figure 3. Cells were
then stained with either a monoclonal antibody to the C-
terminal Myc-epitope in APOBEC3G together with a pol-
yclonal Vif antibody (Fig. 4, panels A & D), or a polyclonal
Myc antibody together with a monoclonal Vif antiserum
(Fig. 4, panels B & E). A third set of cells was stained with
a polyclonal APOBEC3G-specific antiserum together with
the monoclonal Vif antibody (Fig. 4, panels C & F). Rep-
resentative fields are shown for each combination.
To quantify the results, multiple optical fields were ana-
lyzed (n = 5–10) with a total of at least 100 transfected
cells for each parameter. As can be seen in figure 5, meth-
anol-fixed samples showed a relatively modest variation
among the three antibodies used. All three antibodies
identified between 45% to 60% of the cells as double-pos-
itive for Vif and APOBEC3G. In contrast, formaldehyde-
fixed samples exhibited a larger antibody-dependent vari-
ation. Staining with the 9E10 monoclonal antibody to the
Myc-epitope in APOBEC3G yielded the lowest efficiency
of staining and identified little more than 40% of the
transfected cells as double-positive for Vif and
APOBEC3G. In contrast, staining of APOBEC3G was
more efficient with the polyclonal Myc antibody, which
identified approximately 80% of the transfected cells as
double-positive in formaldehyde-fixed samples. Finally,
the polyclonal APOBEC3G-specific antibody was slightly
less efficient for the staining of FA-fixed samples than
methanol-fixed samples and identified about 40% of the
formaldehyde-fixed samples as double-positive. Since all
samples were derived from the same transfected culture,
variations in the co-expression of Vif and APOBEC3G in
the individual samples can only be explained by the dif-
ferential sensitivity of the antibodies to the fixation
procedure.
Exclusion of APOBEC3G from cells expressing biologically 
inactive Vif protein
Under optimal conditions, wild type Vif and APOBEC3G
were coexpressed in about 80% of transfected cells (see
figure 5). Thus, 20% of the transfected cell population
either was expressing Vif but not APOBEC3G or was sin-
gle-positive for APOBEC3G. To investigate whether the
presence of such single-positive cells is due to an activity
of Vif or is a general characteristic of transiently trans-
fected cells, we studied the effects of a biologically inactive
Vif variant. For this purpose, we employed a Vif mutant
carrying a deletion of residues 23–45 in Vif. We previously
showed that this mutant is unable to rescue viral infectiv-
ity in APOBEC3G-expressing cells [4]. Like wild type Vif,
Vif∆23–43 was expressed in the context of the subviralRetrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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expression vector pNL-A1. HeLa cells were cotransfected
with pNL-A1/Vif∆23–43 and pHIV-APO3G, fixed with
methanol and processed for confocal microscopy as
described for figure 2. As shown in figure 6, coexpression
of Vif∆23–43 and APOBEC3G yielded a significant
number of double-positive cells (white arrow heads).
However, as observed before with wild type Vif, we also
identified cells that were Vif-positive but had significantly
reduced APOBEC3G levels (Fig. 6, blue arrow heads) or
cells that were APOBEC3G positive but did not express Vif
(yellow arrow heads). As with wild type Vif, overlay of the
Vif and APOBEC3G image channels suggested a partial
colocalization of the two proteins. In cells, in which Vif
had spontaneously collapsed into a perinuclear aggregate
(green arrow head), APOBEC3G did not exhibit a similar
change in subcellular distribution. This is in contrast to
the Vif-induced reorganization of vimentin reported pre-
viously [22]. Thus, Vif∆23–43 is either unable to interact
with APOBEC3G or forms complexes that are unstable.
These results also imply that the partial colocalization of
APOBEC3G and Vif noted in this study may not reflect a
true physical interaction of the two proteins.
Rescue of viral infectivity and Vif-induced reduction of 
cellular APOBEC3G levels are not directly linked
The combined results from the experiments shown in fig-
ures 2,3,4,5,6, do not support the notion that Vif expres-
sion leads to the elimination of APOBEC3G from Vif-
positive cells. It can be argued, however, that under the
experimental conditions employed in our experiments,
the Vif expression levels were insufficient or ineffective. To
control for this possibility, we compared the infectivity of
Tat-dependent expression of APOBEC3G Figure 3
Tat-dependent expression of APOBEC3G. HeLa cells were transfected with pNL-A1 and pHIV-APO3G at a 1:1 molar ratio. 
Transfected cells were grown on cover slips for 24 hr and then either fixed with ice-cold methanol (panels A-C) or with for-
maldehyde buffer as described in Methods (panels D-F). Cells were stained with an APOBEC3G-specific antibody (A & D) and 
a Vif monoclonal antibody (B & E) as in figure 2 and analyzed on a confocal microscope. Panels C & F are overlays of panels A 
& B and D & E, respectively. Arrow heads are defined as follows: white = APOBEC3G:Vif-double-positive cells; yellow = Vif-
negative cells; blue = APOBEC3G negative cells.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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viruses produced in the presence of various ratios of Vif
and APOBEC3G. To allow a direct comparison with the
experiments shown in figures 2 to 6, Vif and APOBEC3G
were expressed in trans from pNL-A1 and pHIV-APO3G
respectively in the presence of a Vif-defective NL4-3 provi-
ral vector. The ratios of Vif to APOBEC3G expression vec-
tor were 1:1, 2:1, and 5:1, respectively. Note that the Vif to
APOBEC3G ratio in the experiments shown in figures 2 to
4 was 1:1 throughout. A Vif-negative sample was analyzed
as negative control. Virus-containing supernatants were
harvested 24 hr after transfection, normalized for equal
reverse transcriptase activity and used for the infection of
LuSIV indicator cells. Relative virus infectivity was deter-
mined by comparing the Tat-dependent expression of
luciferase in the target cells (Fig. 7). Interestingly, viruses
produced at the lowest Vif:APOBEC3G ratio were virtually
as infectious as viruses produced in the presence of higher
levels of Vif. In fact, increasing the Vif:APOBEC3G ratio to
2:1 or 5:1 did not significantly increase viral infectivity.
Instead, at the 5:1 ratio viral infectivity was slightly
reduced, presumably due to the inhibitory effect of Vif at
high concentrations as reported previously [39]. Taken
together, our data suggest that the inability of Vif to
prevent co-expression of APOBEC3G in transiently trans-
fected HeLa cells is not caused by sub-optimal levels of Vif
or a lack of Vif activity in our system.
Discussion
APOBEC3G is able to deaminate cytidine residues on the
HIV minus-strand cDNA and cause hypermutation of the
viral genome. Nevertheless, HIV-1 is able to efficiently
replicate in APOBEC3G expressing cells thanks to the
activity of the accessory protein Vif. One of the prerequi-
sites for the antiviral activity of APOBEC3G is that it is
Effect of fixation method and antibody choice on co-expression of Vif and APOBEC3G Figure 4
Effect of fixation method and antibody choice on co-expression of Vif and APOBEC3G. HeLa cells were transfected with pNL-
A1 and pHIV-APO3G as described in figure 3. Cells were grown on cover slips for 24 hr and then either fixed with ice-cold 
methanol (panels A-C) or with formaldehyde buffer as in figure 3 (panels D-F) and stained with the following combinations of 
antibodies: (A & D) polyclonal Vif + anti-Myc MAb 9E10; (B & E) anti-Vif MAb #319 + anti-Myc polyclonal antibody; (C & F) 
anti-Vif MAb #319 + anti-APO3G polyclonal antibody. Vif was visualized using Cy2-conjugated secondary antibodies (green) 
and APOBEC3G was visualized with Texas red-conjugated antibodies (red). Areas of overlap appear as yellow.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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Quantitative analysis of Vif and APOBEC3G co-expression Figure 5
Quantitative analysis of Vif and APOBEC3G co-expression. Samples from figure 4 were analyzed for the expression of Vif (grey 
bars) or APOBEC3G (white bars) or for double-positive cells (black bars). Between 5 and 10 independent optical fields were 
analyzed to yield at least 100 transfected cells. Error bars reflect standard deviations calculated from multiple optical fields. The 
results obtained with methanol-fixed samples (MeOH) are on the left; results from formaldehyde-fixed samples (FA) are on the 
right.
Co-expression of APOBEC3G and a biologically inactive Vif variant Figure 6
Co-expression of APOBEC3G and a biologically inactive Vif variant. HeLa cells were transfected with pHIV-APO3G and pNL-
A1/Vif∆23–43, encoding a biologically inactive Vif variant. Cells were fixed in methanol and stained with the monoclonal Vif 
antibody (MAb #319; green) and a rabbit polyclonal antibody to APOBEC3G (red) as described above. APOBEC3G is shown in 
panel A; panel B depicts samples stained for Vif; panel C is the merged image of panels A & B. White and yellow arrow heads 
depict APOBEC3G:Vif double-positive and Vif-negative cells, respectively. Blue arrow heads point to double-positive cells that 
show reduced levels of APOBEC3G; the green arrow head depicts a cell where Vif is concentrated around the microtubule 
organizing center without a similar effect on APOBEC3G.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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packaged into the virions where it selectively targets the
viral minus-strand cDNA [5,10-12,40,41] and there is
convincing evidence that HIV-1 Vif plays an important
role in inhibiting the encapsidation of APOBEC3G. The
question of how Vif accomplishes this remains under
investigation. A number of groups have reported on the
rapid Vif-induced degradation of APOBEC3G by cellular
proteasomes [3,6-9,27,28]. Consistent with this, treat-
ment of cells with proteasome inhibitors was found to
increase APOBEC3G expression levels despite the pres-
ence of Vif [6,7,9,28]. This is contrasted by other reports
that noted only a moderate effect of Vif on cellular
APOBEC3G levels [4,5]. In fact, our own studies with pro-
teasome inhibitors did not yield a significant increase in
APOBEC3G levels in the presence of Vif (manuscript in
preparation). Nevertheless, the currently prevailing opin-
ion is that Vif inhibits the encapsidation of APOBEC3G by
inducing its rapid degradation in virus-producing cells.
While the results from our own study argue against a
depletion of APOBEC3G in Vif-expressing cells – thus
implying that Vif can rescue viral infectivity despite the
presence of APOBEC3G in virus-producing cells – it is
important to point out that our data do not rule out the
possibility that Vif – under different experimental condi-
tions – can indeed mediate the proteasome dependent
degradation of APOBEC3G. In fact, expression of Vif from
a codon-optimized vector consistently had a more pro-
nounced effect on APOBEC3G steady-state levels than Vif
expressed from pNL-A1 even though the Vif expression
levels from the codon-optimized construct were consist-
ently several-fold lower than those from pNL-A1 (manu-
script in preparation). Experiments are ongoing to study
the differential effects of Vif expressed from pNL-A1 and
Vif expressed from a codon-optimized vector on
APOBEC3G stability. However, these results could suggest
that the effect of Vif on APOBEC3G steady-state levels
may be influenced by the context in which Vif is
expressed. At any rate, despite our inability to observe Vif-
dependent cellular depletion of APOBEC3G, we were
invariably able to recover fully infectious HIV under con-
ditions were the intracellular levels of APOBEC3G were
only moderately affected. We therefore conclude that (i)
Vif has the ability to rescue viral infectivity even in the
presence of APOBEC3G and (ii) that intracellular deple-
tion of APOBEC3G and rescue of viral infectivity may be
functionally separable activities of Vif.
For now, the reason for the differences in the sensitivity of
APOBEC3G to Vif noted by us versus other research
groups remains unexplained. APOBEC3G can form oligo-
meric structures and is able to interact with Vif. It is there-
fore possible that such complexes undergo
conformational changes that can mask epitopes thus lim-
iting the access of antibodies used in the experiments.
Thus, the discrepancy between our findings of the
coexpression of Vif and APOBEC3G in the majority of
cells and the virtual exclusion of APOBEC3G from Vif-
expressing cells reported by Marin et al. [6] may be attrib-
uted at least in part to differences in the experimental pro-
tocols. It is unlikely that the observed discrepancies are
strain-specific variations. To this end we have compared
the activities of two HIV-1 Vif isolates, HXB2 and NL4-3,
which differ by 18 amino acids (9.4%), and found them
to be equally active against APOBEC3G (manuscript in
preparation). It is unclear why cotransfection of pHIV-
APO3G with pNL-A1 produces a fraction of cells that are
single-positive for Vif or for APOBEC3G. Since
APOBEC3G expression from the pHIV-APO3G vector is
strictly Tat-dependent, the results cannot be explained by
differential transfection of cells with individual plasmids.
Vif efficiently rescues viral infectivity Figure 7
Vif efficiently rescues viral infectivity. HeLa cells were trans-
fected with the vif-defective proviral vector pNL4-3vif(-) 
together with pNL-A1 and pHIV-APO3G at 1:1, 2:1, or 5:1 
molar ratios. Cell lysates and purified, concentrated viral 
extracts were analyzed by immunoblotting using antibodies 
to APOBEC3G (APO3G), Vif (MAb #319), or an HIV-posi-
tive human serum for the identification of viral capsid protein 
(CA). Virus-containing, filtered supernatants were normal-
ized for equal reverse transcriptase activity and used for the 
infection of the LuSIV indicator cell line [38]. Virus-induced 
luciferase activity was measured 24 hr after infection as 
described in Methods. Relative light units (RLU), which are 
directly proportional to the infectivity of the viruses, are 
shown. Error bars reflect standard deviations from duplicate 
experiments.Retrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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Also, this phenomenon is clearly not a consequence of Vif
function, since similar results were observed in the pres-
ence of a biologically inactive Vif variant (Fig. 6) or when
APOBEC3G was co-expressed with HIV-1 Gag in the
absence of Vif (data not shown).
The inability of Vif expressed from pNL-A1 to deplete
APOBEC3G is consistent with our previous inability to
observe APOBEC3G degradation in kinetic studies [4].
More recent in-depth kinetic analyses of APOBEC3G
employing multiple epitope tags and various antibodies
confirm these initial findings and suggest that – instead of
inducing APOBEC3G degradation – Vif induces confor-
mational changes in APOBEC3G that affect the ability of
antibodies to interact with the protein (manuscript in
preparation). Experiments are ongoing to study the nature
of the APOBEC3G/Vif complexes and to further decipher
the mechanism(s) by which Vif inhibits the encapsidation
of APOBEC3G under conditions of no or low intracellular
degradation.
Conclusions
Expression of Vif and APOBEC3G in our experimental
setup does not lead to the elimination of APOBEC3G
from Vif expressing cells. In fact, more than 80% of suc-
cessfully transfected cells efficiently co-expressed both
proteins. Similar results were observed when a biologi-
cally inactive Vif variant was co-expressed with
APOBEC3G suggesting that the absence of APOBEC3G in
some of the Vif-positive cells is not due to Vif-mediated
APOBEC3G degradation but reflects a general characteris-
tic of the transient expression system. Moreover,
APOBEC3G expression levels were very similar for Vif-
positive and Vif-negative cells as judged from the immu-
nostaining consistent with the only modest reduction in
APOBEC3G steady-state levels observed in our immunob-
lot analyses. Nevertheless, viruses produced under such
conditions were fully infectious in the presence but not in
the absence of Vif attesting to the biological activity of all
the proteins involved and demonstrating that Vif was
expressed at saturating levels. We conclude that produc-
tion of infectious viruses from APOBEC3G expressing
cells is dependent on Vif but does not necessitate
APOBEC3G exclusion from virus-producing cells.
Methods
Plasmids
The full-length molecular clone pNL4-3 [33] was used for
the production of wild type infectious virus. For transient
expression of Vif, the subgenomic expression vector pNL-
A1 [34] was employed. This plasmid expresses all HIV-1
proteins except for gag and pol products. A vif-defective
variant of pNL-A1, pNL-A1vif(-) was constructed by
deletion of an NdeI/PflMI fragment [4]. Plasmid pNL-A1/
Vif∆23–43 expresses a Vif variant carrying a 21 amino acid
deletion (residues 23 to 43) in its vif gene as reported else-
where [4]. This Vif variant is inactive and does not target
APOBEC3G [4]. Plasmids pcDNA-APO3G and pHIV-
APO3G are vectors for the expression of human
APOBEC3G under the control of the CMV immediate
early promoter or the HIV promoter, respectively, and
were constructed as described elsewhere [4].
Antisera
Serum from an HIV-positive patient (APS) was used to
detect HIV-1-specific capsid (CA) proteins. A monoclonal
antibody to Vif (MAb #319) was used for all immunoblot
analyses and some of the immunohistochemical analyses
as indicated in the text and was obtained from Michael
Malim through the NIH AIDS Research and Reference
Reagent Program [23,35,36,36,37] For all other immuno-
cytochemical analyses our Vif-specific polyclonal anti-
body (Vif93) was employed. APOBEC3G, carrying a C-
terminal Myc epitope tag was identified either with the
Myc-specific 9E10 monoclonal antibody or a polyclonal
antibodies to the Myc epitope tag (both antibodies were
obtained from Sigma-Aldrich, St. Louis). Alternatively,
APOBEC3G was identified using a polyclonal rabbit
serum against recombinant APOBEC3G [4]. Tubulin was
identified using a monoclonal antibody to α-tubulin
(Sigma-Aldrich, St. Louis).
Tissue culture and transfections
HeLa cells were propagated in Dulbecco's modified Eagles
medium (DMEM) containing 10% fetal bovine serum
(FBS). LuSIV cells are derived from CEMx174 cells and
contain a luciferase indicator gene under the control of
the SIVmac239 LTR [38]. These cells were obtained
through the NIH AIDS Research and Reference Reagent
Program and were maintained in complete RPMI 1640
medium supplemented with 10% FBS and hygromycin B
(300 µg/ml).
For transfection of HeLa cells, cells were grown in 25 cm2
flasks to about 80% confluency. Cells were transfected
using LipofectAMINE PLUS™ (Invitrogen Corp, Carlsbad
CA) following the manufacturer's recommendations. A
total of 5–6 µg of plasmid DNA per 25 cm2 flask was used.
Cells were harvested 24 hr post-transfection. Transfection
efficiency in our analyses was generally 30% to 40%.
Preparation of virus stocks
Virus stocks were prepared by transfecting HeLa cells with
appropriate plasmid DNAs. Virus-containing superna-
tants were harvested 24 hr after transfection. Cellular
debris was removed by centrifugation (3 min, 3000 × g)
and clarified supernatants were filtered (0.45 µm) to
remove residual cellular contaminants. For determination
of viral infectivity, unconcentrated filtered viral superna-
tants were used for the infection of indicator cells. ForRetrovirology 2004, 1:27 http://www.retrovirology.com/content/1/1/27
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immunoblot analysis of viral proteins, virus particles (7
ml) were concentrated by ultracentrifugation through 4
ml of 20% sucrose in PBS as described before [4].
Immunoblotting
For immunoblot analysis of intracellular proteins, whole
cell lysates were prepared as follows: Cells were washed
once with PBS, suspended in PBS (400 µl/107 cells), and
mixed with an equal volume of sample buffer (4%
sodium dodecyl sulfate, 125 mM Tris-HCl, pH 6.8, 10%
2-mercaptoethanol, 10% glycerol, and 0.002% bromphe-
nol blue). Proteins were solubilized by boiling for 10 to
15 min at 95°C with occasional vortexing of the samples
to shear chromosomal DNA. Residual insoluble material
was removed by centrifugation (2 min, 15000 rpm in
Eppendorf Minifuge). Viral proteins were obtained by
boiling concentrated viral pellets in a 1:1 mixture of PBS
and sample buffer. Cell lysates and viral extracts were sub-
jected to SDS-PAGE; proteins were transferred to PVDF
membranes and reacted with appropriate antibodies as
described in the text. Membranes were then incubated
with horseradish peroxidase-conjugated secondary anti-
bodies (Amersham Biosciences, Piscataway NJ) and visu-
alized by enhanced chemiluminescence (ECL, Amersham
Biosciences).
Infectivity assay
To determine viral infectivity, virus stocks were normal-
ized for equal reverse transcriptase activity and used to
infect LuSIV cells (5 × 105) in a 24-well plate total volume
1.2 to 1.4 ml. Cells were incubated for 24 hours at 37°C.
Cells were then harvested and lysed in 150 µl of Promega
1x reporter lysis buffer (Promega Corp., Madison WI). To
determine the luciferase activity in the lysates, 50 µl of
each lysate were combined with luciferase substrate
(Promega Corp., Madison WI) by automatic injection and
light emission was measured for 10 seconds at room
temperature in a luminometer (Optocomp II, MGM
Instruments, Hamden CT).
Immunocytochemistry
For the analysis of transfected HeLa cells, cells were
scraped off the flasks 3 hr after transfection and reseeded
into 12 well plates containing 0.13 mm cover slips. Cells
were grown for 15 to 24 hrs at 37°C in DMEM containing
10% FBS. Cells were then fixed at -20°C in precooled
methanol (-20°C) for 10 min followed by two washes in
PBS or fixed in FA buffer (5% formaldehyde + 2% sucrose
in PBS) for 20 min at room temperature followed by two
washes in PBS. Coverslips were stored in PBS at 4°C until
use. FA-fixed samples were permeabilized for 30 min at
room temperature in permeabilization buffer (1% Triton
X-100, 10% sucrose in PBS) prior to incubation with
antibodies. For antibody staining, cover slips were incu-
bated in a humid chamber at 37°C for 30 min with pri-
mary antibodies at appropriate dilutions in 1% BSA in
PBS. Cover slips were washed once in PBS (5 min, room
temp) and incubated with Texas-Red- or Cy2-conjugated
secondary antibodies (diluted in 1% BSA in PBS) for 30
min at 37°C in a humid chamber. Cover slips were then
washed twice with PBS and mounted onto microscope
slides with glycerol gelatin (Sigma-Aldrich, St. Louis) con-
taining 0.1M N-propyl gallate (Sigma-Aldrich, St. Louis)
to prevent photo bleaching and were stored at 4°C in the
dark until analyzed by confocal microscopy.
Confocal Microscopy
For confocal microscopy, a Zeiss LSM410 inverted laser
scanning microscope was employed. The microscope was
equipped with a krypton/argon mixed-gas laser and was
operated by the Microcosm Renaissance 410 (v2.3.4) soft-
ware package. Images were acquired with a Plan-Apochro-
mat 63x/1.4 oil immersion objective (Carl Zeiss,
Thornwood). Additional optical magnification (up to 5-
fold) was achieved using the zoom feature of the image
acquisition software. For two-color analysis, objects were
excited using 488/568 nm laser lines. Green and red emis-
sions were recorded through appropriate filters (515–540
nm band pass filter for Cy2 and 590 nm long pass filter for
Texas-Red) and stored in separate (red and green) image
channels. At the same time, bright field images (Nomarski
optics) were collected and stored in a third (blue) chan-
nel. Image quality was enhanced during data acquisition
using the Renaissance 410 line average feature (8 or 16x).
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